KR100722578B1 - 비오틴-결합 수용체 분자 - Google Patents
비오틴-결합 수용체 분자 Download PDFInfo
- Publication number
- KR100722578B1 KR100722578B1 KR1020007009270A KR20007009270A KR100722578B1 KR 100722578 B1 KR100722578 B1 KR 100722578B1 KR 1020007009270 A KR1020007009270 A KR 1020007009270A KR 20007009270 A KR20007009270 A KR 20007009270A KR 100722578 B1 KR100722578 B1 KR 100722578B1
- Authority
- KR
- South Korea
- Prior art keywords
- thr
- leu
- glu
- ser
- asn
- Prior art date
Links
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 title claims abstract description 41
- 229960002685 biotin Drugs 0.000 title claims abstract description 21
- 239000011616 biotin Substances 0.000 title claims abstract description 21
- 235000020958 biotin Nutrition 0.000 title claims abstract description 20
- 230000027455 binding Effects 0.000 title claims abstract description 16
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 27
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 24
- 230000001086 cytosolic effect Effects 0.000 claims abstract description 6
- 108090001008 Avidin Proteins 0.000 claims description 21
- 102000005962 receptors Human genes 0.000 claims description 13
- 108020003175 receptors Proteins 0.000 claims description 13
- 102000035013 scavenger receptor class A Human genes 0.000 claims description 10
- 108091005451 scavenger receptor class A Proteins 0.000 claims description 10
- 108010090804 Streptavidin Proteins 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 6
- 230000005714 functional activity Effects 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims 2
- 238000003259 recombinant expression Methods 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000001159 endocytotic effect Effects 0.000 claims 1
- 102000035160 transmembrane proteins Human genes 0.000 abstract description 2
- 108091005703 transmembrane proteins Proteins 0.000 abstract description 2
- 102000037865 fusion proteins Human genes 0.000 description 16
- 108020001507 fusion proteins Proteins 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 13
- 239000002299 complementary DNA Substances 0.000 description 11
- 239000013598 vector Substances 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 241001430294 unidentified retrovirus Species 0.000 description 6
- 241000282326 Felis catus Species 0.000 description 4
- 206010018338 Glioma Diseases 0.000 description 4
- RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000012202 endocytosis Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 108010051242 phenylalanylserine Proteins 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 108010026333 seryl-proline Proteins 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- XWJBVGZSIAZDKJ-FXQIFTODSA-N 2-[3-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]propyl]propanedioic acid Chemical class N1C(=O)N[C@@H]2[C@H](CCCC(C(=O)O)C(O)=O)SC[C@@H]21 XWJBVGZSIAZDKJ-FXQIFTODSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 108010049041 glutamylalanine Proteins 0.000 description 3
- 108010015792 glycyllysine Proteins 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- BUANFPRKJKJSRR-ACZMJKKPSA-N Ala-Ala-Gln Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](C)C(=O)N[C@H](C([O-])=O)CCC(N)=O BUANFPRKJKJSRR-ACZMJKKPSA-N 0.000 description 2
- NXSFUECZFORGOG-CIUDSAMLSA-N Ala-Asn-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NXSFUECZFORGOG-CIUDSAMLSA-N 0.000 description 2
- GWFSQQNGMPGBEF-GHCJXIJMSA-N Ala-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)N GWFSQQNGMPGBEF-GHCJXIJMSA-N 0.000 description 2
- KTXKIYXZQFWJKB-VZFHVOOUSA-N Ala-Thr-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O KTXKIYXZQFWJKB-VZFHVOOUSA-N 0.000 description 2
- OMSKGWFGWCQFBD-KZVJFYERSA-N Ala-Val-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OMSKGWFGWCQFBD-KZVJFYERSA-N 0.000 description 2
- NONSEUUPKITYQT-BQBZGAKWSA-N Arg-Asn-Gly Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)O)N)CN=C(N)N NONSEUUPKITYQT-BQBZGAKWSA-N 0.000 description 2
- AUFHLLPVPSMEOG-YUMQZZPRSA-N Arg-Gly-Glu Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O AUFHLLPVPSMEOG-YUMQZZPRSA-N 0.000 description 2
- LVMUGODRNHFGRA-AVGNSLFASA-N Arg-Leu-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O LVMUGODRNHFGRA-AVGNSLFASA-N 0.000 description 2
- UZGFHWIJWPUPOH-IHRRRGAJSA-N Arg-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N UZGFHWIJWPUPOH-IHRRRGAJSA-N 0.000 description 2
- CLICCYPMVFGUOF-IHRRRGAJSA-N Arg-Lys-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O CLICCYPMVFGUOF-IHRRRGAJSA-N 0.000 description 2
- NYDIVDKTULRINZ-AVGNSLFASA-N Arg-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N NYDIVDKTULRINZ-AVGNSLFASA-N 0.000 description 2
- JCROZIFVIYMXHM-GUBZILKMSA-N Arg-Met-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CCCN=C(N)N JCROZIFVIYMXHM-GUBZILKMSA-N 0.000 description 2
- FRBAHXABMQXSJQ-FXQIFTODSA-N Arg-Ser-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O FRBAHXABMQXSJQ-FXQIFTODSA-N 0.000 description 2
- OQPAZKMGCWPERI-GUBZILKMSA-N Arg-Ser-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O OQPAZKMGCWPERI-GUBZILKMSA-N 0.000 description 2
- LLQIAIUAKGNOSE-NHCYSSNCSA-N Arg-Val-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N LLQIAIUAKGNOSE-NHCYSSNCSA-N 0.000 description 2
- IOTKDTZEEBZNCM-UGYAYLCHSA-N Asn-Asn-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O IOTKDTZEEBZNCM-UGYAYLCHSA-N 0.000 description 2
- MSBDSTRUMZFSEU-PEFMBERDSA-N Asn-Glu-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O MSBDSTRUMZFSEU-PEFMBERDSA-N 0.000 description 2
- IBLAOXSULLECQZ-IUKAMOBKSA-N Asn-Ile-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC(N)=O IBLAOXSULLECQZ-IUKAMOBKSA-N 0.000 description 2
- HMUKKNAMNSXDBB-CIUDSAMLSA-N Asn-Met-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O HMUKKNAMNSXDBB-CIUDSAMLSA-N 0.000 description 2
- UXHYOWXTJLBEPG-GSSVUCPTSA-N Asn-Thr-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UXHYOWXTJLBEPG-GSSVUCPTSA-N 0.000 description 2
- RSMIHCFQDCVVBR-CIUDSAMLSA-N Asp-Gln-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CCCNC(N)=N RSMIHCFQDCVVBR-CIUDSAMLSA-N 0.000 description 2
- AYFVRYXNDHBECD-YUMQZZPRSA-N Asp-Leu-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O AYFVRYXNDHBECD-YUMQZZPRSA-N 0.000 description 2
- IWLZBRTUIVXZJD-OLHMAJIHSA-N Asp-Thr-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O IWLZBRTUIVXZJD-OLHMAJIHSA-N 0.000 description 2
- MRYDJCIIVRXVGG-QEJZJMRPSA-N Asp-Trp-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O MRYDJCIIVRXVGG-QEJZJMRPSA-N 0.000 description 2
- FIRWLDUOFOULCA-XIRDDKMYSA-N Asp-Trp-Lys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N FIRWLDUOFOULCA-XIRDDKMYSA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- GGRDJANMZPGMNS-CIUDSAMLSA-N Cys-Ser-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O GGRDJANMZPGMNS-CIUDSAMLSA-N 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- PONUFVLSGMQFAI-AVGNSLFASA-N Gln-Asn-Phe Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PONUFVLSGMQFAI-AVGNSLFASA-N 0.000 description 2
- XFKUFUJECJUQTQ-CIUDSAMLSA-N Gln-Gln-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O XFKUFUJECJUQTQ-CIUDSAMLSA-N 0.000 description 2
- KDXKFBSNIJYNNR-YVNDNENWSA-N Gln-Glu-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KDXKFBSNIJYNNR-YVNDNENWSA-N 0.000 description 2
- UWMDGPFFTKDUIY-HJGDQZAQSA-N Gln-Pro-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O UWMDGPFFTKDUIY-HJGDQZAQSA-N 0.000 description 2
- JKDBRTNMYXYLHO-JYJNAYRXSA-N Gln-Tyr-Leu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 JKDBRTNMYXYLHO-JYJNAYRXSA-N 0.000 description 2
- AKJRHDMTEJXTPV-ACZMJKKPSA-N Glu-Asn-Ala Chemical compound C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCC(O)=O)C(O)=O AKJRHDMTEJXTPV-ACZMJKKPSA-N 0.000 description 2
- ILGFBUGLBSAQQB-GUBZILKMSA-N Glu-Glu-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ILGFBUGLBSAQQB-GUBZILKMSA-N 0.000 description 2
- JGHNIWVNCAOVRO-DCAQKATOSA-N Glu-His-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O JGHNIWVNCAOVRO-DCAQKATOSA-N 0.000 description 2
- AOCARQDSFTWWFT-DCAQKATOSA-N Glu-Met-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O AOCARQDSFTWWFT-DCAQKATOSA-N 0.000 description 2
- GGEJHJIXRBTJPD-BYPYZUCNSA-N Gly-Asn-Gly Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O GGEJHJIXRBTJPD-BYPYZUCNSA-N 0.000 description 2
- DGKBSGNCMCLDSL-BYULHYEWSA-N Gly-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN DGKBSGNCMCLDSL-BYULHYEWSA-N 0.000 description 2
- GLACUWHUYFBSPJ-FJXKBIBVSA-N Gly-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN GLACUWHUYFBSPJ-FJXKBIBVSA-N 0.000 description 2
- PLCAEMGSYOYIPP-GUBZILKMSA-N His-Ser-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 PLCAEMGSYOYIPP-GUBZILKMSA-N 0.000 description 2
- NZOCIWKZUVUNDW-ZKWXMUAHSA-N Ile-Gly-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O NZOCIWKZUVUNDW-ZKWXMUAHSA-N 0.000 description 2
- KFVUBLZRFSVDGO-BYULHYEWSA-N Ile-Gly-Asp Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O KFVUBLZRFSVDGO-BYULHYEWSA-N 0.000 description 2
- MQFGXJNSUJTXDT-QSFUFRPTSA-N Ile-Gly-Ile Chemical compound N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)O MQFGXJNSUJTXDT-QSFUFRPTSA-N 0.000 description 2
- AKOYRLRUFBZOSP-BJDJZHNGSA-N Ile-Lys-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)O)N AKOYRLRUFBZOSP-BJDJZHNGSA-N 0.000 description 2
- VEPIBPGLTLPBDW-URLPEUOOSA-N Ile-Phe-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N VEPIBPGLTLPBDW-URLPEUOOSA-N 0.000 description 2
- FXJLRZFMKGHYJP-CFMVVWHZSA-N Ile-Tyr-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N FXJLRZFMKGHYJP-CFMVVWHZSA-N 0.000 description 2
- WIYDLTIBHZSPKY-HJWJTTGWSA-N Ile-Val-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 WIYDLTIBHZSPKY-HJWJTTGWSA-N 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- OIARJGNVARWKFP-YUMQZZPRSA-N Leu-Asn-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O OIARJGNVARWKFP-YUMQZZPRSA-N 0.000 description 2
- OGCQGUIWMSBHRZ-CIUDSAMLSA-N Leu-Asn-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O OGCQGUIWMSBHRZ-CIUDSAMLSA-N 0.000 description 2
- BPANDPNDMJHFEV-CIUDSAMLSA-N Leu-Asp-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O BPANDPNDMJHFEV-CIUDSAMLSA-N 0.000 description 2
- ILJREDZFPHTUIE-GUBZILKMSA-N Leu-Asp-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ILJREDZFPHTUIE-GUBZILKMSA-N 0.000 description 2
- ZTLGVASZOIKNIX-DCAQKATOSA-N Leu-Gln-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ZTLGVASZOIKNIX-DCAQKATOSA-N 0.000 description 2
- GLBNEGIOFRVRHO-JYJNAYRXSA-N Leu-Gln-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O GLBNEGIOFRVRHO-JYJNAYRXSA-N 0.000 description 2
- LIINDKYIGYTDLG-PPCPHDFISA-N Leu-Ile-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LIINDKYIGYTDLG-PPCPHDFISA-N 0.000 description 2
- JNDYEOUZBLOVOF-AVGNSLFASA-N Leu-Leu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O JNDYEOUZBLOVOF-AVGNSLFASA-N 0.000 description 2
- LXKNSJLSGPNHSK-KKUMJFAQSA-N Leu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N LXKNSJLSGPNHSK-KKUMJFAQSA-N 0.000 description 2
- RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 2
- OVZLLFONXILPDZ-VOAKCMCISA-N Leu-Lys-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OVZLLFONXILPDZ-VOAKCMCISA-N 0.000 description 2
- KQFZKDITNUEVFJ-JYJNAYRXSA-N Leu-Phe-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)CC1=CC=CC=C1 KQFZKDITNUEVFJ-JYJNAYRXSA-N 0.000 description 2
- JGKHAFUAPZCCDU-BZSNNMDCSA-N Leu-Tyr-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CC=C(O)C=C1 JGKHAFUAPZCCDU-BZSNNMDCSA-N 0.000 description 2
- SWWCDAGDQHTKIE-RHYQMDGZSA-N Lys-Arg-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SWWCDAGDQHTKIE-RHYQMDGZSA-N 0.000 description 2
- WLCYCADOWRMSAJ-CIUDSAMLSA-N Lys-Asn-Cys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(O)=O WLCYCADOWRMSAJ-CIUDSAMLSA-N 0.000 description 2
- YVSHZSUKQHNDHD-KKUMJFAQSA-N Lys-Asn-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N YVSHZSUKQHNDHD-KKUMJFAQSA-N 0.000 description 2
- NDORZBUHCOJQDO-GVXVVHGQSA-N Lys-Gln-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O NDORZBUHCOJQDO-GVXVVHGQSA-N 0.000 description 2
- VEGLGAOVLFODGC-GUBZILKMSA-N Lys-Glu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O VEGLGAOVLFODGC-GUBZILKMSA-N 0.000 description 2
- ULUQBUKAPDUKOC-GVXVVHGQSA-N Lys-Glu-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O ULUQBUKAPDUKOC-GVXVVHGQSA-N 0.000 description 2
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 2
- KUQWVNFMZLHAPA-CIUDSAMLSA-N Met-Ala-Gln Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O KUQWVNFMZLHAPA-CIUDSAMLSA-N 0.000 description 2
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 2
- 108010087066 N2-tryptophyllysine Proteins 0.000 description 2
- 108010047562 NGR peptide Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- MPGJIHFJCXTVEX-KKUMJFAQSA-N Phe-Arg-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O MPGJIHFJCXTVEX-KKUMJFAQSA-N 0.000 description 2
- HCTXJGRYAACKOB-SRVKXCTJSA-N Phe-Asn-Asp Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N HCTXJGRYAACKOB-SRVKXCTJSA-N 0.000 description 2
- LDSOBEJVGGVWGD-DLOVCJGASA-N Phe-Asp-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 LDSOBEJVGGVWGD-DLOVCJGASA-N 0.000 description 2
- GYEPCBNTTRORKW-PCBIJLKTSA-N Phe-Ile-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O GYEPCBNTTRORKW-PCBIJLKTSA-N 0.000 description 2
- MJAYDXWQQUOURZ-JYJNAYRXSA-N Phe-Lys-Gln Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O MJAYDXWQQUOURZ-JYJNAYRXSA-N 0.000 description 2
- AAERWTUHZKLDLC-IHRRRGAJSA-N Phe-Pro-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O AAERWTUHZKLDLC-IHRRRGAJSA-N 0.000 description 2
- BSKMOCNNLNDIMU-CDMKHQONSA-N Phe-Thr-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O BSKMOCNNLNDIMU-CDMKHQONSA-N 0.000 description 2
- SXMSEHDMNIUTSP-DCAQKATOSA-N Pro-Lys-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O SXMSEHDMNIUTSP-DCAQKATOSA-N 0.000 description 2
- KYKKKSWGEPFUMR-NAKRPEOUSA-N Ser-Arg-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KYKKKSWGEPFUMR-NAKRPEOUSA-N 0.000 description 2
- HJEBZBMOTCQYDN-ACZMJKKPSA-N Ser-Glu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HJEBZBMOTCQYDN-ACZMJKKPSA-N 0.000 description 2
- CJINPXGSKSZQNE-KBIXCLLPSA-N Ser-Ile-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O CJINPXGSKSZQNE-KBIXCLLPSA-N 0.000 description 2
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 2
- PCMZJFMUYWIERL-ZKWXMUAHSA-N Ser-Val-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O PCMZJFMUYWIERL-ZKWXMUAHSA-N 0.000 description 2
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 description 2
- BSNZTJXVDOINSR-JXUBOQSCSA-N Thr-Ala-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O BSNZTJXVDOINSR-JXUBOQSCSA-N 0.000 description 2
- YLXAMFZYJTZXFH-OLHMAJIHSA-N Thr-Asn-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O YLXAMFZYJTZXFH-OLHMAJIHSA-N 0.000 description 2
- GCXFWAZRHBRYEM-NUMRIWBASA-N Thr-Gln-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O GCXFWAZRHBRYEM-NUMRIWBASA-N 0.000 description 2
- LAFLAXHTDVNVEL-WDCWCFNPSA-N Thr-Gln-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N)O LAFLAXHTDVNVEL-WDCWCFNPSA-N 0.000 description 2
- MPUMPERGHHJGRP-WEDXCCLWSA-N Thr-Gly-Lys Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)N)O MPUMPERGHHJGRP-WEDXCCLWSA-N 0.000 description 2
- PAXANSWUSVPFNK-IUKAMOBKSA-N Thr-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N PAXANSWUSVPFNK-IUKAMOBKSA-N 0.000 description 2
- MECLEFZMPPOEAC-VOAKCMCISA-N Thr-Leu-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O MECLEFZMPPOEAC-VOAKCMCISA-N 0.000 description 2
- AKHDFZHUPGVFEJ-YEPSODPASA-N Thr-Val-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AKHDFZHUPGVFEJ-YEPSODPASA-N 0.000 description 2
- VEYXZZGMIBKXCN-UBHSHLNASA-N Trp-Asp-Asp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N VEYXZZGMIBKXCN-UBHSHLNASA-N 0.000 description 2
- SNJAPSVIPKUMCK-NWLDYVSISA-N Trp-Glu-Thr Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SNJAPSVIPKUMCK-NWLDYVSISA-N 0.000 description 2
- HHPSUFUXXBOFQY-AQZXSJQPSA-N Trp-Thr-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N)O HHPSUFUXXBOFQY-AQZXSJQPSA-N 0.000 description 2
- KSCVLGXNQXKUAR-JYJNAYRXSA-N Tyr-Leu-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O KSCVLGXNQXKUAR-JYJNAYRXSA-N 0.000 description 2
- AUMNPAUHKUNHHN-BYULHYEWSA-N Val-Asn-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N AUMNPAUHKUNHHN-BYULHYEWSA-N 0.000 description 2
- JLFKWDAZBRYCGX-ZKWXMUAHSA-N Val-Asn-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N JLFKWDAZBRYCGX-ZKWXMUAHSA-N 0.000 description 2
- URIRWLJVWHYLET-ONGXEEELSA-N Val-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)C(C)C URIRWLJVWHYLET-ONGXEEELSA-N 0.000 description 2
- AGXGCFSECFQMKB-NHCYSSNCSA-N Val-Leu-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N AGXGCFSECFQMKB-NHCYSSNCSA-N 0.000 description 2
- VENKIVFKIPGEJN-NHCYSSNCSA-N Val-Met-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N VENKIVFKIPGEJN-NHCYSSNCSA-N 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 description 2
- 108010038850 arginyl-isoleucyl-tyrosine Proteins 0.000 description 2
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 2
- 238000004630 atomic force microscopy Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 2
- 108010078144 glutaminyl-glycine Proteins 0.000 description 2
- 108010027668 glycyl-alanyl-valine Proteins 0.000 description 2
- 108010019832 glycyl-asparaginyl-glycine Proteins 0.000 description 2
- 208000029824 high grade glioma Diseases 0.000 description 2
- 108010078274 isoleucylvaline Proteins 0.000 description 2
- 108010009298 lysylglutamic acid Proteins 0.000 description 2
- 201000011614 malignant glioma Diseases 0.000 description 2
- 108010084572 phenylalanyl-valine Proteins 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000013605 shuttle vector Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 108010009962 valyltyrosine Proteins 0.000 description 2
- LWUWMHIOBPTZBA-DCAQKATOSA-N Ala-Arg-Lys Chemical compound NC(=N)NCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CCCCN)C(O)=O LWUWMHIOBPTZBA-DCAQKATOSA-N 0.000 description 1
- DCVYRWFAMZFSDA-ZLUOBGJFSA-N Ala-Ser-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DCVYRWFAMZFSDA-ZLUOBGJFSA-N 0.000 description 1
- VRTOMXFZHGWHIJ-KZVJFYERSA-N Ala-Thr-Arg Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VRTOMXFZHGWHIJ-KZVJFYERSA-N 0.000 description 1
- NVWJMQNYLYWVNQ-BYULHYEWSA-N Asn-Ile-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O NVWJMQNYLYWVNQ-BYULHYEWSA-N 0.000 description 1
- YYSYDIYQTUPNQQ-SXTJYALSSA-N Asn-Ile-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O YYSYDIYQTUPNQQ-SXTJYALSSA-N 0.000 description 1
- VITDJIPIJZAVGC-VEVYYDQMSA-N Asn-Met-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VITDJIPIJZAVGC-VEVYYDQMSA-N 0.000 description 1
- ATHZHGQSAIJHQU-XIRDDKMYSA-N Asn-Trp-Lys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N ATHZHGQSAIJHQU-XIRDDKMYSA-N 0.000 description 1
- ZELQAFZSJOBEQS-ACZMJKKPSA-N Asp-Asn-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZELQAFZSJOBEQS-ACZMJKKPSA-N 0.000 description 1
- KLYPOCBLKMPBIQ-GHCJXIJMSA-N Asp-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC(=O)O)N KLYPOCBLKMPBIQ-GHCJXIJMSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- JLZCAZJGWNRXCI-XKBZYTNZSA-N Cys-Thr-Glu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O JLZCAZJGWNRXCI-XKBZYTNZSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- SNLOOPZHAQDMJG-CIUDSAMLSA-N Gln-Glu-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SNLOOPZHAQDMJG-CIUDSAMLSA-N 0.000 description 1
- KASDBWKLWJKTLJ-GUBZILKMSA-N Glu-Glu-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O KASDBWKLWJKTLJ-GUBZILKMSA-N 0.000 description 1
- KRGZZKWSBGPLKL-IUCAKERBSA-N Glu-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)N KRGZZKWSBGPLKL-IUCAKERBSA-N 0.000 description 1
- JWNZHMSRZXXGTM-XKBZYTNZSA-N Glu-Ser-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JWNZHMSRZXXGTM-XKBZYTNZSA-N 0.000 description 1
- PUUYVMYCMIWHFE-BQBZGAKWSA-N Gly-Ala-Arg Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PUUYVMYCMIWHFE-BQBZGAKWSA-N 0.000 description 1
- XBWMTPAIUQIWKA-BYULHYEWSA-N Gly-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CN XBWMTPAIUQIWKA-BYULHYEWSA-N 0.000 description 1
- VUUOMYFPWDYETE-WDSKDSINSA-N Gly-Gln-Cys Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)CN VUUOMYFPWDYETE-WDSKDSINSA-N 0.000 description 1
- NTOWAXLMQFKJPT-YUMQZZPRSA-N Gly-Glu-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CN NTOWAXLMQFKJPT-YUMQZZPRSA-N 0.000 description 1
- WNZOCXUOGVYYBJ-CDMKHQONSA-N Gly-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN)O WNZOCXUOGVYYBJ-CDMKHQONSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 101000805729 Homo sapiens V-type proton ATPase 116 kDa subunit a 1 Proteins 0.000 description 1
- 101000854879 Homo sapiens V-type proton ATPase 116 kDa subunit a 2 Proteins 0.000 description 1
- 101000854873 Homo sapiens V-type proton ATPase 116 kDa subunit a 4 Proteins 0.000 description 1
- PNDMHTTXXPUQJH-RWRJDSDZSA-N Ile-Glu-Thr Chemical compound N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@H](O)C)C(=O)O PNDMHTTXXPUQJH-RWRJDSDZSA-N 0.000 description 1
- NURNJECQNNCRBK-FLBSBUHZSA-N Ile-Thr-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NURNJECQNNCRBK-FLBSBUHZSA-N 0.000 description 1
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- CFZZDVMBRYFFNU-QWRGUYRKSA-N Leu-His-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)NCC(O)=O CFZZDVMBRYFFNU-QWRGUYRKSA-N 0.000 description 1
- XVZCXCTYGHPNEM-UHFFFAOYSA-N Leu-Leu-Pro Natural products CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O XVZCXCTYGHPNEM-UHFFFAOYSA-N 0.000 description 1
- DPURXCQCHSQPAN-AVGNSLFASA-N Leu-Pro-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DPURXCQCHSQPAN-AVGNSLFASA-N 0.000 description 1
- FDBTVENULFNTAL-XQQFMLRXSA-N Leu-Val-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N FDBTVENULFNTAL-XQQFMLRXSA-N 0.000 description 1
- LCMWVZLBCUVDAZ-IUCAKERBSA-N Lys-Gly-Glu Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)NCC(=O)N[C@H](C([O-])=O)CCC([O-])=O LCMWVZLBCUVDAZ-IUCAKERBSA-N 0.000 description 1
- LUAJJLPHUXPQLH-KKUMJFAQSA-N Lys-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCCN)N LUAJJLPHUXPQLH-KKUMJFAQSA-N 0.000 description 1
- IOQWIOPSKJOEKI-SRVKXCTJSA-N Lys-Ser-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IOQWIOPSKJOEKI-SRVKXCTJSA-N 0.000 description 1
- OOXVBECOTYHTCK-WDSOQIARSA-N Met-Trp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCSC)N OOXVBECOTYHTCK-WDSOQIARSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102100025386 Oxidized low-density lipoprotein receptor 1 Human genes 0.000 description 1
- 101710199789 Oxidized low-density lipoprotein receptor 1 Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- NHCKESBLOMHIIE-IRXDYDNUSA-N Phe-Gly-Phe Chemical compound C([C@H](N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 NHCKESBLOMHIIE-IRXDYDNUSA-N 0.000 description 1
- BONHGTUEEPIMPM-AVGNSLFASA-N Phe-Ser-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O BONHGTUEEPIMPM-AVGNSLFASA-N 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- NMELOOXSGDRBRU-YUMQZZPRSA-N Pro-Glu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCCN1 NMELOOXSGDRBRU-YUMQZZPRSA-N 0.000 description 1
- FYPGHGXAOZTOBO-IHRRRGAJSA-N Pro-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@@H]2CCCN2 FYPGHGXAOZTOBO-IHRRRGAJSA-N 0.000 description 1
- SVXXJYJCRNKDDE-AVGNSLFASA-N Pro-Pro-His Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NCCC1)C1=CN=CN1 SVXXJYJCRNKDDE-AVGNSLFASA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108010053763 Pyruvate Carboxylase Proteins 0.000 description 1
- 102100039895 Pyruvate carboxylase, mitochondrial Human genes 0.000 description 1
- 101150090155 R gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- SRTCFKGBYBZRHA-ACZMJKKPSA-N Ser-Ala-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SRTCFKGBYBZRHA-ACZMJKKPSA-N 0.000 description 1
- COAHUSQNSVFYBW-FXQIFTODSA-N Ser-Asn-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O COAHUSQNSVFYBW-FXQIFTODSA-N 0.000 description 1
- OHKLFYXEOGGGCK-ZLUOBGJFSA-N Ser-Asp-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O OHKLFYXEOGGGCK-ZLUOBGJFSA-N 0.000 description 1
- MPPHJZYXDVDGOF-BWBBJGPYSA-N Ser-Cys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CO MPPHJZYXDVDGOF-BWBBJGPYSA-N 0.000 description 1
- DJACUBDEDBZKLQ-KBIXCLLPSA-N Ser-Ile-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O DJACUBDEDBZKLQ-KBIXCLLPSA-N 0.000 description 1
- ZOPISOXXPQNOCO-SVSWQMSJSA-N Ser-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CO)N ZOPISOXXPQNOCO-SVSWQMSJSA-N 0.000 description 1
- FPCGZYMRFFIYIH-CIUDSAMLSA-N Ser-Lys-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O FPCGZYMRFFIYIH-CIUDSAMLSA-N 0.000 description 1
- VLMIUSLQONKLDV-HEIBUPTGSA-N Ser-Thr-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VLMIUSLQONKLDV-HEIBUPTGSA-N 0.000 description 1
- HKHCTNFKZXAMIF-KKUMJFAQSA-N Ser-Tyr-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC1=CC=C(O)C=C1 HKHCTNFKZXAMIF-KKUMJFAQSA-N 0.000 description 1
- 241000186983 Streptomyces avidinii Species 0.000 description 1
- JNQZPAWOPBZGIX-RCWTZXSCSA-N Thr-Arg-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@@H](C)O)CCCN=C(N)N JNQZPAWOPBZGIX-RCWTZXSCSA-N 0.000 description 1
- VYEHBMMAJFVTOI-JHEQGTHGSA-N Thr-Gly-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O VYEHBMMAJFVTOI-JHEQGTHGSA-N 0.000 description 1
- RPECVQBNONKZAT-WZLNRYEVSA-N Thr-Tyr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H]([C@@H](C)O)N RPECVQBNONKZAT-WZLNRYEVSA-N 0.000 description 1
- SPIFGZFZMVLPHN-UNQGMJICSA-N Thr-Val-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SPIFGZFZMVLPHN-UNQGMJICSA-N 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- CCZXBOFIBYQLEV-IHPCNDPISA-N Trp-Leu-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(O)=O CCZXBOFIBYQLEV-IHPCNDPISA-N 0.000 description 1
- BXPOOVDVGWEXDU-WZLNRYEVSA-N Tyr-Ile-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BXPOOVDVGWEXDU-WZLNRYEVSA-N 0.000 description 1
- SINRIKQYQJRGDQ-MEYUZBJRSA-N Tyr-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 SINRIKQYQJRGDQ-MEYUZBJRSA-N 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 102100020737 V-type proton ATPase 116 kDa subunit a 4 Human genes 0.000 description 1
- NMPXRFYMZDIBRF-ZOBUZTSGSA-N Val-Asn-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N NMPXRFYMZDIBRF-ZOBUZTSGSA-N 0.000 description 1
- YKNOJPJWNVHORX-UNQGMJICSA-N Val-Phe-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=CC=C1 YKNOJPJWNVHORX-UNQGMJICSA-N 0.000 description 1
- USLVEJAHTBLSIL-CYDGBPFRSA-N Val-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C USLVEJAHTBLSIL-CYDGBPFRSA-N 0.000 description 1
- 102100039066 Very low-density lipoprotein receptor Human genes 0.000 description 1
- 101710177612 Very low-density lipoprotein receptor Proteins 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 108700021042 biotin binding protein Proteins 0.000 description 1
- 102000043871 biotin binding protein Human genes 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108010079547 glutamylmethionine Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 108010036413 histidylglycine Proteins 0.000 description 1
- 108010085325 histidylproline Proteins 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 1
- 108010000761 leucylarginine Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 108010038320 lysylphenylalanine Proteins 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108010015796 prolylisoleucine Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 108700026215 vpr Genes Proteins 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
단백질이 세포질 도메인, 막-스패닝 도메인 및 세포외 도메인을 포함하며, 여기서 세포외 도메인이 비오틴-결합 활성을 갖는, 비오틴화된 분자에 결합할 수 있는 신규의 막횡단 단백질.
Description
본 발명은 비오틴-결합 활성을 갖는 막-스패닝 단백질(membrane-spanning proteins)에 관한 것이다.
비오틴(비타민 H)은 혈액 및 조직에서 저농도로 발견되는, 물에 쉽게 용해되는 물질이다. 비오틴의 생물학적 역할은 활성화된 CO2의 담체로서, 부가적 자유 에너지 없이도 수용체에 CO2를 전달하게 한다. 활성화된 카르복시비오틴은 보통 카르복시비오틴의 형성에 필요한 효소에 부착된다. 예를 들면, 비오틴은, 아세틸 CoA의 존재 하에, 카르복시비오틴의 형성 및 피루베이트에 활성화된 카르복실기의 연이은 전이를 촉매하여 옥살로아세테이트를 형성하는 피루베이트 카르복실라제에 부착될 수 있다.
비오틴은 또한, 아비딘(달걀 흰자위로부터의 63 kDa 당단백질) 및 스트렙타비딘(스트렙토미세스 아비디니(Streptomyces avidinii) 세균속으로부터의 비당화된 단백질)에 자연적으로 가장 높은 친화성(affinities)을 갖는 것들 중 하나와 결합한다. 결합은 특성(Ka 1015 mol-1)에 있어서 거의 비가역적이다. 아비딘과 비오틴 사이의 친화성은 광범위의 생물분석 응용에 매우 유용한 것으로 증명되어 왔다. 예를 들면, 아비딘-비오틴 복합체는, 광범위의 검출계에 성공적으로 사용되어 왔으며, 여기서 표적 분자는 그것의 카르복시 말단을 통해서 비오틴과 결합하여 비오틴화된 분자를 형성하며, 이 비오틴화된 분자는 용액에서 쉽게 검출 또는 분리될 수 있다. 비오틴화는 각종 분자들의 생물학적 및 이화학적 특성들을 변화시키지 않고, 아비딘에 비오틴 보결분자족(prosthetic group)의 결합능에 영향을 주지 않으면서 일어날 수 있다.
본 발명들은 이제 아비딘 및 스트렙타비딘의 비오틴-결합 활성이 비오틴화된 분자들과 결합할 수 있는 막횡단 단백질(transmembrane proteins)의 생산에 이용할 수 있다는 것이 알려지게 하였다.
본 발명의 단백질은 세포질 도메인, 막-스패닝 도메인 및 세포외 도메인을 포함할 수 있으며, 여기서 세포외 도메인은 비오틴 결합 활성을 가질 수 있다. 세포외 도메인은 아비딘 또는 스트렙타비딘의 기능 활성을 가질 수 있다.
본 발명의 단백질은 세포질 도메인, 막-스패닝 도메인 및 세포외 도메인을 포함할 수 있으며, 여기서 세포외 도메인은 비오틴 결합 활성을 가질 수 있다. 세포외 도메인은 아비딘 또는 스트렙타비딘의 기능 활성을 가질 수 있다.
본 발명의 단백질 또는 핵산 분자를 사용해서, 조직 중의 특정 부위에 비오틴화된 분자를 표적화하는 것이 가능하다. 이 방법에서 표적화된 분자들은, 분자들이 세포내 또는 세포 표면에서 그들의 효과를 발휘하도록 하는, 엔도사이토시스(endocytosis)에 의해 조직 또는 세포에 흡수될 수 있다.
도 1은 본 발명의 융합 단백질의 도해도이고, 여기서 A는 아비딘을 나타내며, B는 엔도사이토시스 수용체의 막-스패닝 도메인을 나타내고 (및 C는 비오틴을 나타냄);
도 2는 셔틀 벡타를 사용한 클로닝 전략(단계)의 도해도이고,
도 3은 레트로바이러스 벡타를 사용한 클로닝 전략의 도해도이다.
발명의 설명
본 발명의 단백질은 종래의 재조합 DNA 기술을 사용하여 생산될 수 있다. 전형적으로, 아비딘, 스트렙타비딘 또는 관련 단백질 등의 비오틴-결합 단밸질의 기능 도메인을 위한 DNA 서열 코딩(coding)은 막-스패닝 특성을 갖는 단백질의 DNA 서열 코딩을 포함하는 유전적 구조물로 꾀하여 진다(engineered). 아비딘 및 스트렙타비딘-관련 단백질의 예로 AVR-1-AVR-5, AVR-X-AVR-V, Stv1 및 Stv2가 포함된다.
본 발명의 단백질은 종래의 재조합 DNA 기술을 사용하여 생산될 수 있다. 전형적으로, 아비딘, 스트렙타비딘 또는 관련 단백질 등의 비오틴-결합 단밸질의 기능 도메인을 위한 DNA 서열 코딩(coding)은 막-스패닝 특성을 갖는 단백질의 DNA 서열 코딩을 포함하는 유전적 구조물로 꾀하여 진다(engineered). 아비딘 및 스트렙타비딘-관련 단백질의 예로 AVR-1-AVR-5, AVR-X-AVR-V, Stv1 및 Stv2가 포함된다.
융합 단백질의 개별 도메인은 폴리머라제 연쇄 반응에 의해 증폭되거나, 제한 효소 소화, 단리 및 정제(예를 들면, 전기영동을 사용하여)시키고, 이어서 결찰(예를 들면, DNA 리가제를 사용하여)을 사용해서 모(parent) cDNA로부터 단리될 수 있다. 그리고 나서, 융합 단백질 구조물은 적당한 숙주 세포로 트랜스펙션, 배양, 및 표준 단백질 정제 기술을 사용하여 단리될 수 있다.
상기 구조물은 또한 네이키드(naked) DNA 또는 플라스미드/리포솜, 플라스미드/폴리에틸렌이민, 플라스미드/덴드리머 또는 플라스미드/펩티드 복합체로서 사용될 수 있다.
다른 방법으로, 구조물은 생체내의 특정 위치로 구조물을 표적화하기 위해 사용될 수 있는 복제-결핍 바이러스에 도입될 수 있다. 예를 들면, 구조물은 융합 단백질의 적당한 cDNA를 포함하는 레트로바이러스성 벡타일 수 있다. 그리고 나서, 예를 들면, 몰로니(Moloney) 뮤린 레트로바이로스와 같은, 복제-결핍 레트로바이러스가 표적 세포 및 조직의 안정한 트랜스펙션을 위해 사용될 수 있다. 사용할 수 있는 기타의 바이러스는 복제-결핍 아데노바이러스, 아데노-관련 바이러스, 포진 바이러스, 유두종 바이러스 및 시니비스(sinibis) 바이러스가 포함된다. 그외의 바이러스들은 당업자들에게 명확하게 될 것이다.
아비딘, 스트렙타비딘 또는 관련 단백질의 기능 도메인 이외에, 융합 단백질은 전형적으로 엔도사이도시스 수용체의 막-스패닝 도메인을 포함할 것이다. 이들 수용체들의 사용은 표적 세포내로 비오틴화된 분자를 섭취할 수 있게 한다. 본 발명에 사용될 수 있는 적합한 수용체는 스캐벤저(scavenger) 수용체 클라스 A, 저밀도의 지질단백질 수용체, 매우 낮은 밀도의 지질단백질 수용체, 트랜스페린 수용체 및 LOX-1 수용체를 포함한다. 융합 단백질은 또한 수용체 단백질과 아비딘 펩티드 서열 사이의 링커(linker)를 포함할 수 있다. 링커는 융합 단백질의 다른 성분들의 기능 활성이 보유되다면 어떠한 길이도 가능하다.
일반적으로, 아비딘 또는 스트렙타비딘 펩티드 서열 및 수용체 펩티드 서열 사이의 융합은 수용체 단백질의 세포외 도메인과 아비딘 또는 스트렙타비딘의 비오틴-결합 부위의 모든(any) 부위 바깥쪽 사이에 있다.
다음의 실시예로 본 발명을 설명한다.
실시예
DNA 구조물을 소 스캐벤저 수용체 클라스 A(ScR) (Kodama et al. (1990) Nature 343: 531~535)와 아비딘(Green (1975) Adv. Prot. Chem. 29: 85~133) 사이에서 생성했고, 이것은 ScR 세포질 도메인, 막-스패닝 도메인 및 α-나선으로 감겨진 도메인을 가지며, 비오틴 결합 도메인에 결찰된 단백질을 코드한다. 융합 단백질의 완전한 아미노산 서열은 SEQ ID No.2에 나타냈으며, 여기서 아미노산 1~53은 세포질 도메인을 나타내고, 아미노산 55~79는 막횡단 도메인을 나타내고, 아미노산 81~111은 스페이서 도메인을 나타내고, 아미노산 113~272은 α-나선형으로 감겨진 도메인을 나타낸다. 아미노산 273~400은 분비 신호가 결여된 아비딘 cDNA(Gope et al. (1987) Nucleic Acid Res. 15: 3595~3606)로부터 유도된 성숙 아비딘 펩티드 서열을 나타낸다.
간략하게, ScR의 cDNA는 내부 라우스 육종 바이러스 프로모터(internal Rous Sarcoma Virus Promoter) 및 HindIII 제한 부위를 갖는 ScR cDNA를 함유하는 플라스미드(PLScRNL)로 미리 트랜스펙션된 배양 세포로부터 얻었다. 그 다음, 단리된 cDNA를 레트로바이러스 벡타 pLS1ARNL의 HindIII 부위에 삽입했다. 아비딘 cDNA를 폴리머라제 연쇄반응에 의해 생산하고, 그리고 나서 ScR cDNA 상의 Sty 1 제한 부위에서 레트로바이러스 벡타로 삽입했다. 본 발명을 구체화하는 cDNA는 SEQ ID No.1에 나타냈고, 여기서 뉴클레오티드 1~989는 Mo-MuSV로 부터의 긴 말단 반복을 나타내고; 뉴클레오티드 1071~2270은 융합 단백질의 코딩 영역을 나타내고; 뉴클레오티드 2376~3101은 소 스캐벤저 수용체 I cDNA로부터의 비번역 영역을 나타내고; 뉴클레오티드 3107~3376은 RSV 프로모터 영역을 나타내고; 뉴클레오티드 3727~4522는 신생(neo) R 유전자를 나타내고; 뉴클레오티드 4540~5177은 Mo-MuLV로부터의 긴 말단 반복을 나타낸다.
도 2 및 3은 이 실시예에서 사용한 방법을 언급한다. 더욱 구체적으로, 도 2 는 내부 RSV 프로모터를 갖는 ScR cDNA를 HindIII에 의해 플라스미드 pLScRNL로 부터 절단해서, 셔틀 벡타의 HindIII 위치로 클로닝하는 방법을 나타낸 것이다. 도 3은 ScR-아비딘-RSV cDNA를 레트로바이러스 벡타 pLRNL HindIII 위치로 클로닝하는 방법을 나타낸 것이다.
벡타로 트랜스펙션된 세포 중의 융합 단백질의 발현은 노던 블로팅 및 아비딘에 대한 항체로 면역세포화학적 염색에 의해 확인될 수 있다.
실험한 결과, 완전한 mRNA 전사물은 55 kDa 단량체로 번역되는 것으로 나타났으며, 상기 단량체는 비환원 조건 하에서 S-S 결합에 의해 부착된 110 kDa 이량체의 이차 구조를 형성할 수 있었다. 변성 조건을 사용해서, 대략 110 kDa 이량체 및 55 kDa 단량체 펩티드를 검출했다. 이 결과는 단량체 융합 단백질, 45 kDa의 컴퓨터 계산치에 필적한다. 비변성 조건(즉, 웨스턴 블로팅에 앞서 아세틸화를 사용하여)에서, 가장 강한 신호는 대략 220 kDa이었으며, 이것은 사량체 형성을 암시하는 대략 110 kDa 이량체 및 55 kDa 단량체로 변성되었다. 또한, 220 kDa 단백질의 존재는, 화학적 가교제, 예를 들면, NHS-에스테르를 사용해 증명했다. 결과들은 아비딘이 용해된 채로 남고, 엔도사이토시스 수용체의 막-스패닝 도메인에 부착되었을 때조차 사량체를 형성할 수 있는 것을 나타냈다.
융합 단백질은 동초점(confocal) 현미경 및 원자력(atomic force) 현미경에 의한 분석시, FITC-비오틴과 결합할 수 있는 기능 단백질로 나타났다. 형질도입되지 않은 세포 및 LacZ 유전자를 함유하는 레트로바이러스 벡타로 트랜스펙션된 세포를 대조군으로서 사용했다. LacZ-형질도입된 대조군 세포에 비오틴 프로브의 비-특이적 결합은 원자력 현미경에 의해 검출되지 않았다. 예상한 바와 같이, 트랜스펙션된 세포들은 비고정된 샘플 중에서 반복적으로 측정될 수 있는 특이적 결합을 보였다. 측정된 결합력은 평균 149±19 pN (평균치±평균편차)의 배수였고, 이것은 또한 예상했던대로, 이전에 보고된 비오틴-스트렙다비딘 결합력, 160 pN의 범위내에 있다(Florin et al. (1994), Science 264 : 415~417).
구조물의 기능성은 FACS 분석을 사용하여, 융합 단백질 구조물을 갖는 세포에 형광-표지된 비오틴 분자들의 결합을 보여줌에 의해 생체내에서도 확인될 수 있다.
생체내에서 융합 단백질의 기능 활성은 래트 악성 신경교종 모델 중에서 분석되었다. BT4C 야생-유형 신경교종 세포들을 동계교배한 BDIX 암컷 래트 뇌 중의 2.5 mm의 깊이에서 우측 뇌량 중의 두개골내로 이식했다. 종양의 성장을 고해상(high resolution) MRI(자기공명영상)로 자주 모니터링했다. 종양 세포 접종 3주 후, 각각 2 x 106 cfu/ml 및 1.3 x 106 cofu/ml의 적정량 중의 융합 단백질 또는 LacZ 유전자의 cDNA를 지니는 슈도타입(pseudotype) 레트로바이러스는 처음에는 2.5 mm의 깊이에서, 이어서 1.5 mm의 깊이에서 10분의 간격으로 종양으로 전달되었다. 유전자 전달(transfer)은 성장 2일 후에 반복되었다. 동물들을 희생시키고, 최종 접종후 3일째, 4% PFA로 관류-고정시켰다. 뇌를 제거하고, 접종 부위에서 2개의 관상 조각으로 나누고, 얼음 위에서 절편화하고, 항-아비딘 항체에 대한 면역반응성을 사용해 분석했다. 결과들은 융합 단백질이 생체내의 래트 악성 신경교종 중에서 발현되는 것을 나타냈다. 단백질은 신경교종 및 종양 혈관 중의 혈관 내피 세포를 닮은 고리와 같은 구조 중에서 검출되었다.
<110> EUROGENE LIMITED
<120> BIOTIN-BINDING RECEPTOR MOLECULES
<130> 20000822
<150> GB9803757.5
<151> 1998-02-23
<150> GB9813653.4
<151> 1998-06-24
<160> 2
<170> KopatentIn 1.55
<210> 1
<211> 5177
<212> DNA
<213> Artificial Sequence
<220>
<223> A DNA construct was created between the bovine scavenger recepto
r class A (ScR) and avidin, which codes for a protein having a Sc
R cytoplasmic domain, membrane-spanning domain and alpha-helical
coiled domain, ligated to a biotin-binding domain.
<220>
<221> CDS
<222> (1071)..(2270)
<400> 1
tttgaaagac cccacccgta ggtggcaagc tagcttaagt aacgccactt tgcaaggcat 60
ggaaaaatac ataactgaga atagaaaagt tcagatcaag gtcaggaaca aagaaacagc 120
tgaataccaa acaggatatc tgtggtaagc ggttcctgcc ccggctcagg gccaagaaca 180
gatgagacag ctgagtgatg ggccaaacag gatatctgtg gtaagcagtt cctgccccgg 240
ctcggggcca agaacagatg gtccccagat gcggtccagc cctcagcagt ttctagtgaa 300
tcatcagatg tttccagggt gccccaagga cctgaaaatg accctgtacc ttatttgaac 360
taaccaatca gttcgcttct cgcttctgtt cgcgcgcttc cgctctccga gctcaataaa 420
agagcccaca acccctcact cggcgcgcca gtcttccgat agactgcgtc gcccgggtac 480
ccgtattccc aataaagcct cttgctgttt gcatccgaat cgtggtctcg ctgttccttg 540
ggagggtctc ctctgagtga ttgactaccc acgacggggg tctttcattt gggggctcgt 600
ccgggatttg gagacccctg cccagggacc accgacccac caccgggagg taagctggcc 660
agcaacttat ctgtgtctgt ccgattgtct agtgtctatg tttgatgtta tgcgcctgcg 720
tctgtactag ttagctaact agctctgtat ctggcggacc cgtggtggaa ctgacgagtt 780
ctgaacaccc ggccgcaacc ctgggagacg tcccagggac tttgggggcc gtttttgtgg 840
cccgacctga ggaagggagt cgatgtggaa tccgaccccg tcaggatatg tggttctggt 900
aggagacgag aacctaaaac agttcccgcc tccgtctgaa tttttgcttt cggtttggaa 960
ccgaagccgc gcgtcttgtc tgctgcagcc aagcttgggc tgcaggtcga ctctagagga 1020
tcaattcggc acgagtaaat cggtgctgcc gtctttacca catatgaagt atg gca cag 1079
Met Ala Gln
1
tgg gat gac ttt cct gat cag caa gag gac act gac agc tgt aca gag 1127
Trp Asp Asp Phe Pro Asp Gln Gln Glu Asp Thr Asp Ser Cys Thr Glu
5 10 15
tct gtg aag ttc gat gct cgc tca gtg aca gct ttg ctt cct ccc cat 1175
Ser Val Lys Phe Asp Ala Arg Ser Val Thr Ala Leu Leu Pro Pro His
20 25 30 35
cct aaa aat ggc cca act ctt caa gag agg atg aag tct tat aaa act 1223
Pro Lys Asn Gly Pro Thr Leu Gln Glu Arg Met Lys Ser Tyr Lys Thr
40 45 50
gca ctg atc acc ctt tat ctc att gtg ttt gta gtt ctc gtg ccc atc 1271
Ala Leu Ile Thr Leu Tyr Leu Ile Val Phe Val Val Leu Val Pro Ile
55 60 65
att ggc ata gtg gca gct cag ctc ctg aaa tgg gaa acg aag aat tgc 1319
Ile Gly Ile Val Ala Ala Gln Leu Leu Lys Trp Glu Thr Lys Asn Cys
70 75 80
acg gtt ggc tca gtt aat gca gat ata tct cca agt ccg gaa ggc aaa 1367
Thr Val Gly Ser Val Asn Ala Asp Ile Ser Pro Ser Pro Glu Gly Lys
85 90 95
gga aat ggc agt gaa gat gaa atg aga ttt cga gaa gct gtg atg gaa 1415
Gly Asn Gly Ser Glu Asp Glu Met Arg Phe Arg Glu Ala Val Met Glu
100 105 110 115
cgc atg agc aac atg gaa agc aga atc cag tat ctt tca gat aat gaa 1463
Arg Met Ser Asn Met Glu Ser Arg Ile Gln Tyr Leu Ser Asp Asn Glu
120 125 130
gcc aat ctc cta gat gct aag aat ttc caa aat ttc agc ata aca act 1511
Ala Asn Leu Leu Asp Ala Lys Asn Phe Gln Asn Phe Ser Ile Thr Thr
135 140 145
gat caa aga ttt aat gat gtt ctt ttc cag cta aat tcc tta ctt tcc 1559
Asp Gln Arg Phe Asn Asp Val Leu Phe Gln Leu Asn Ser Leu Leu Ser
150 155 160
tcc atc cag gaa cat gag aat atc ata ggg gat atc tcc aag tca tta 1607
Ser Ile Gln Glu His Glu Asn Ile Ile Gly Asp Ile Ser Lys Ser Leu
165 170 175
gta ggt ctg aac acc aca gta ctt gat ttg cag ttc agt att gaa aca 1655
Val Gly Leu Asn Thr Thr Val Leu Asp Leu Gln Phe Ser Ile Glu Thr
180 185 190 195
ctg aat ggc aga gtc caa gag aat gca ttt aaa caa caa gag gag atg 1703
Leu Asn Gly Arg Val Gln Glu Asn Ala Phe Lys Gln Gln Glu Glu Met
200 205 210
cgt aaa tta gag gag cgt ata tac aat gca tca gca gaa att aag tct 1751
Arg Lys Leu Glu Glu Arg Ile Tyr Asn Ala Ser Ala Glu Ile Lys Ser
215 220 225
cta gat gaa aaa caa gta tat ttg gaa cag gaa ata aaa ggg gaa atg 1799
Leu Asp Glu Lys Gln Val Tyr Leu Glu Gln Glu Ile Lys Gly Glu Met
230 235 240
aaa ctg ttg aat aat atc act aat gat ctg agg ctg aag gat tgg gaa 1847
Lys Leu Leu Asn Asn Ile Thr Asn Asp Leu Arg Leu Lys Asp Trp Glu
245 250 255
cat tct cag aca ttg aaa aat atc act tta ctc caa ggt gcc aga aag 1895
His Ser Gln Thr Leu Lys Asn Ile Thr Leu Leu Gln Gly Ala Arg Lys
260 265 270 275
tgc tcg ctg act ggg aaa tgg acc aac gat ctg ggc tcc aac atg acc 1943
Cys Ser Leu Thr Gly Lys Trp Thr Asn Asp Leu Gly Ser Asn Met Thr
280 285 290
atc ggg gct gtg aac agc aga ggt gaa ttc aca ggc acc tac atc aca 1991
Ile Gly Ala Val Asn Ser Arg Gly Glu Phe Thr Gly Thr Tyr Ile Thr
295 300 305
gcc gta aca gcc aca tca aat gag atc aaa gag tca cca ctg cat ggg 2039
Ala Val Thr Ala Thr Ser Asn Glu Ile Lys Glu Ser Pro Leu His Gly
310 315 320
aca caa aac acc atc aac aag agg acc cag ccc acc ttt ggc ttc acc 2087
Thr Gln Asn Thr Ile Asn Lys Arg Thr Gln Pro Thr Phe Gly Phe Thr
325 330 335
gtc aat tgg aag ttt tca gag tcc acc act gtg ttc acg ggc cag tgc 2135
Val Asn Trp Lys Phe Ser Glu Ser Thr Thr Val Phe Thr Gly Gln Cys
340 345 350 355
ttc ata gac agg aat ggg aag gag gtc ctg aag acc atg tgg ctg ctg 2183
Phe Ile Asp Arg Asn Gly Lys Glu Val Leu Lys Thr Met Trp Leu Leu
360 365 370
cgg tca agt gtt aat gac att ggt gat gac tgg aaa gct acc agg gtc 2231
Arg Ser Ser Val Asn Asp Ile Gly Asp Asp Trp Lys Ala Thr Arg Val
375 380 385
ggc atc aac atc ttc act cgc ctg cgc aca cag aag gag tgagtgagtg 2280
Gly Ile Asn Ile Phe Thr Arg Leu Arg Thr Gln Lys Glu
390 395 400
accaaggtcc tcctggactc caggtgaaaa aggagataga ggccctcctg gacaaaatgg 2340
tataccaggc tttccaggtc taataggtac tccaggtctt aaaggtgatc ggggggatct 2400
ctggtttacc tggagttcga ggattcccag gaccaatggg gaagaccggg aagccaggac 2460
ttaatggaca aaaaggccag aagggagaaa aagggagtgg aagcatgcaa agacaatcta 2520
atacagtccg actggtgggt ggcagcggcc ctcacgaagg cagagtggag atttttcacg 2580
aaggccagtg gggtacggtg tgtgacgacc gctgggaact gcgtggagga ctggtcgtct 2640
gcaggagctt gggatacaaa ggtgttcaaa gtgtgcataa gcgagcttat tttggaaaag 2700
gtacgggtcc aatatggctg aatgaagtat tttgtttcgg gaaagagtca tccattgaag 2760
agtgcagaat tagacagtgg ggtgtgagag cctgttcgca cgacgaagat gctgggggtc 2820
actttgcacc tacataatgc atcatatttt cattcacatt ttttaaactg ttataaagtg 2880
atttttttcc tttgcttcac taaaatcagc ttaattaata tttaagaaac taagaatttt 2940
atccacagaa aaggaatatt taaaaatcac tggataaaca tataaaatag cttcatattt 3000
gcttcaaata ccagaaccat ttcaacttct ctaggttttt aagtggctcg tgccgaattg 3060
atcccctcag gatatagtag tttcgctttt gcatagggag ggggaaatgt agtcttatgc 3120
aatactcttg tagtcttgca acatggtaac gatgagttag caacatgcct tacaaggaga 3180
gaaaaagcac cgtgcatgcc gattggtgga agtaaggtgg tacgatcgtg ccttattagg 3240
aaggcaacag acgggtctga catggattgg acgaaccact gaattccgca ttgcagagat 3300
attgtattta agtgcctagc tcgatacagc aaacgccatt tgaccattca ccacattggt 3360
gtgcacctcc aagcttcacg ctgccgcaag cactcagggc gcaagggctg ctaaaggaag 3420
cggaacacgt agaaagccag tccgcagaaa cggtgctgac cccggatgaa tgtcagctac 3480
tgggctatct ggacaaggga aaacgcaagc gcaaagagaa agcaggtagc ttgcagtggg 3540
cttacatggc gatagctaga ctgggcggtt ttatggacag caagcgaacc ggaattgcca 3600
gctggggcgc cctctggtaa ggttgggaag ccctgcaaag taaactggat ggctttcttg 3660
ccgccaagga tctgatggcg caggggatca agatctgatc aagagacagg atgaggatcg 3720
tttcgcatga ttgaacaaga tggattgcac gcaggttctc cggccgcttg ggtggagagg 3780
ctattcggct atgactgggc acaacagaca atcggctgct ctgatgccgc cgtgttccgg 3840
ctgtcagcgc aggggcgccc ggttcttttt gtcaagaccg acctgtccgg tgccctgaat 3900
gaactgcagg acgaggcagc gcggctatcg tggctggcca cgacgggcgt tccttgcgca 3960
gctgtgctcg acgttgtcac tgaagcggga agggactggc tgctattggg cgaagtgccg 4020
gggcaggatc tcctgtcatc tcaccttgct cctgccgaga aagtatccat catggctgat 4080
gcaatgcggc ggctgcatac gcttgatccg gctacctgcc cattcgacca ccaagcgaaa 4140
catcgcatcg agcgagcacg tactcggatg gaagccggtc ttgtcgatca ggatgatctg 4200
gacgaagagc atcaggggct cgcgccagcc gaactgttcg ccaggctcaa ggcgcgcatg 4260
cccgacggcg aggatctcgt cgtgacccat ggcgatgcct gcttgccgaa tatcatggtg 4320
gaaaatggcc gcttttctgg attcatcgac tgtggccggc tgggtgtggc ggaccgctat 4380
caggacatag cgttggctac ccgtgatatt gctgaagagc ttggcggcga atgggctgac 4440
cgcttcctcg tgctttacgg tatcgccgct cccgattcgc agcgcatcgc cttctatcgc 4500
cttcttgacg agttcttctg agcgggactc tggggttcga taaaataaaa gattttattt 4560
agtctccaga aaaagggggg aatgaaagac cccacctgta ggtttggcaa gctagcttaa 4620
gtaacgccat tttgcaaggc atggaaaaat acataactga gaatagagaa gttcagatca 4680
aggtcaggaa cagatggaac agctgaatat gggccaaaca ggatatctgt ggtaagcagt 4740
tcctgccccg gctcagggcc aagaacagat ggaacagctg aatatgggcc aaacaggata 4800
tctgtggtaa gcagttcctg ccccggctca gggccaagaa cagatggtcc ccagatgcgg 4860
tccagccctc agcagtttct agagaaccat cagatgtttc cagggtgccc caaggacctg 4920
aaatgaccct gtgccttatt tgaactaacc aatcagttcg cttctcgctt ctgttcgcgc 4980
gcttctgctc cccgagctca ataaaagagc ccacaacccc tcactcgggg cgccagtcct 5040
ccgattgact gagtcgcccg ggtacccgtg tatccaataa accctcttgc agttgcatcc 5100
gacttgtggt ctcgctgttc cttgggaggg tctcctctga gtgattgact acccgtcagc 5160
gggggtcttt catttgg 5177
<210> 2
<211> 400
<212> PRT
<213> Artificial Sequence
<400> 2
Met Ala Gln Trp Asp Asp Phe Pro Asp Gln Gln Glu Asp Thr Asp Ser
1 5 10 15
Cys Thr Glu Ser Val Lys Phe Asp Ala Arg Ser Val Thr Ala Leu Leu
20 25 30
Pro Pro His Pro Lys Asn Gly Pro Thr Leu Gln Glu Arg Met Lys Ser
35 40 45
Tyr Lys Thr Ala Leu Ile Thr Leu Tyr Leu Ile Val Phe Val Val Leu
50 55 60
Val Pro Ile Ile Gly Ile Val Ala Ala Gln Leu Leu Lys Trp Glu Thr
65 70 75 80
Lys Asn Cys Thr Val Gly Ser Val Asn Ala Asp Ile Ser Pro Ser Pro
85 90 95
Glu Gly Lys Gly Asn Gly Ser Glu Asp Glu Met Arg Phe Arg Glu Ala
100 105 110
Val Met Glu Arg Met Ser Asn Met Glu Ser Arg Ile Gln Tyr Leu Ser
115 120 125
Asp Asn Glu Ala Asn Leu Leu Asp Ala Lys Asn Phe Gln Asn Phe Ser
130 135 140
Ile Thr Thr Asp Gln Arg Phe Asn Asp Val Leu Phe Gln Leu Asn Ser
145 150 155 160
Leu Leu Ser Ser Ile Gln Glu His Glu Asn Ile Ile Gly Asp Ile Ser
165 170 175
Lys Ser Leu Val Gly Leu Asn Thr Thr Val Leu Asp Leu Gln Phe Ser
180 185 190
Ile Glu Thr Leu Asn Gly Arg Val Gln Glu Asn Ala Phe Lys Gln Gln
195 200 205
Glu Glu Met Arg Lys Leu Glu Glu Arg Ile Tyr Asn Ala Ser Ala Glu
210 215 220
Ile Lys Ser Leu Asp Glu Lys Gln Val Tyr Leu Glu Gln Glu Ile Lys
225 230 235 240
Gly Glu Met Lys Leu Leu Asn Asn Ile Thr Asn Asp Leu Arg Leu Lys
245 250 255
Asp Trp Glu His Ser Gln Thr Leu Lys Asn Ile Thr Leu Leu Gln Gly
260 265 270
Ala Arg Lys Cys Ser Leu Thr Gly Lys Trp Thr Asn Asp Leu Gly Ser
275 280 285
Asn Met Thr Ile Gly Ala Val Asn Ser Arg Gly Glu Phe Thr Gly Thr
290 295 300
Tyr Ile Thr Ala Val Thr Ala Thr Ser Asn Glu Ile Lys Glu Ser Pro
305 310 315 320
Leu His Gly Thr Gln Asn Thr Ile Asn Lys Arg Thr Gln Pro Thr Phe
325 330 335
Gly Phe Thr Val Asn Trp Lys Phe Ser Glu Ser Thr Thr Val Phe Thr
340 345 350
Gly Gln Cys Phe Ile Asp Arg Asn Gly Lys Glu Val Leu Lys Thr Met
355 360 365
Trp Leu Leu Arg Ser Ser Val Asn Asp Ile Gly Asp Asp Trp Lys Ala
370 375 380
Thr Arg Val Gly Ile Asn Ile Phe Thr Arg Leu Arg Thr Gln Lys Glu
385 390 395 400
Claims (25)
- 엔도사이토시스 수용체(endocytotic receptor)의 막-스패닝 도메인 및 비오틴-결합 활성을 갖는 세포외 도메인을 포함하는 단백질로, 상기 세포외 도메인은 아비딘 또는 스트렙타비딘 기능 활성을 갖는 것인 단백질.
- 제 1항에 있어서, 추가로 세포질 도메인을 포함하는 단백질.
- 삭제
- 제 1항 또는 제 2항에 있어서, 상기 수용체는 스캐벤저 수용체 클라스 A인 것인 단백질.
- 제 1항 또는 제 2항에 있어서, 상기 단백질이 SEQ ID NO.2에 정의된 아미노산 서열로 이루어지는 단백질.
- 제 1항 또는 제 2항에 따른 단백질을 암호화하는 핵산 분자.
- 제 6항에 따른 핵산 분자를 포함하는 재조합 발현 벡타.
- 제 1항 또는 제2항에 따른 단백질의 제조방법으로, 세포주를 제 7항에 따른 재조합 발현 벡타로 트랜스펙션 시키고, 트랜스펙션된 세포에서 단백질을 발현시키는 것을 포함하는 제조방법.
- 삭제
- 삭제
- 삭제
- 삭제
- 제 4항에 있어서, 상기 세포외 도메인이 비오틴-결합 도메인을 갖는 아비딘을 포함하는 단백질.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9803757.5 | 1998-02-23 | ||
GBGB9803757.5A GB9803757D0 (en) | 1998-02-23 | 1998-02-23 | Fusion proteins |
GBGB9813653.4A GB9813653D0 (en) | 1998-06-24 | 1998-06-24 | Fusion proteins |
GB9813653.4 | 1998-06-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010085196A KR20010085196A (ko) | 2001-09-07 |
KR100722578B1 true KR100722578B1 (ko) | 2007-05-28 |
Family
ID=26313170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020007009270A KR100722578B1 (ko) | 1998-02-23 | 1999-02-23 | 비오틴-결합 수용체 분자 |
Country Status (16)
Country | Link |
---|---|
US (1) | US7208291B2 (ko) |
EP (1) | EP1056850B1 (ko) |
JP (1) | JP2002504328A (ko) |
KR (1) | KR100722578B1 (ko) |
CN (1) | CN1195852C (ko) |
AT (1) | ATE274058T1 (ko) |
AU (1) | AU750444B2 (ko) |
CA (1) | CA2319039A1 (ko) |
DE (1) | DE69919515T2 (ko) |
DK (1) | DK1056850T3 (ko) |
ES (1) | ES2226340T3 (ko) |
HU (1) | HUP0101614A3 (ko) |
NO (1) | NO328139B1 (ko) |
PL (1) | PL195990B1 (ko) |
PT (1) | PT1056850E (ko) |
WO (1) | WO1999042577A2 (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040209294A1 (en) * | 2002-09-02 | 2004-10-21 | National Food Research Institute | Method to produce a receptor chip using biotinylated protein |
US9623117B2 (en) * | 2011-04-04 | 2017-04-18 | Wisconsin Alumni Research Foundation | Method for selective targeting and entry of bacterial toxins to cells |
DK3083671T3 (da) * | 2013-12-20 | 2020-12-07 | Hutchinson Fred Cancer Res | Mærkede kimære effektormolekyler og receptorer deraf |
US11827904B2 (en) | 2015-04-29 | 2023-11-28 | Fred Hutchinson Cancer Center | Modified stem cells and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987005026A1 (en) * | 1986-02-24 | 1987-08-27 | The Trustees Of Columbia University In The City Of | Dna encoding streptavidin, streptavidin produced therefrom, fused polypeptides which include amino acid sequences present in streptavidin and uses thereof |
WO1997019957A1 (en) * | 1995-11-30 | 1997-06-05 | New York University | High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5135736A (en) * | 1988-08-15 | 1992-08-04 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
CA1340977C (en) | 1988-11-15 | 2000-04-25 | Monty Krieger | Scavenger receptor protein and antibody thereto |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
US5846537A (en) | 1995-06-07 | 1998-12-08 | University Of Rochester | Modified avidin and streptavidin and methods of use thereof |
-
1999
- 1999-02-23 WO PCT/GB1999/000546 patent/WO1999042577A2/en active IP Right Grant
- 1999-02-23 AT AT99906341T patent/ATE274058T1/de not_active IP Right Cessation
- 1999-02-23 EP EP99906341A patent/EP1056850B1/en not_active Expired - Lifetime
- 1999-02-23 DE DE69919515T patent/DE69919515T2/de not_active Expired - Lifetime
- 1999-02-23 CA CA002319039A patent/CA2319039A1/en not_active Abandoned
- 1999-02-23 PL PL99343079A patent/PL195990B1/pl not_active IP Right Cessation
- 1999-02-23 DK DK99906341T patent/DK1056850T3/da active
- 1999-02-23 KR KR1020007009270A patent/KR100722578B1/ko not_active IP Right Cessation
- 1999-02-23 CN CNB998032174A patent/CN1195852C/zh not_active Expired - Fee Related
- 1999-02-23 ES ES99906341T patent/ES2226340T3/es not_active Expired - Lifetime
- 1999-02-23 AU AU26312/99A patent/AU750444B2/en not_active Ceased
- 1999-02-23 HU HU0101614A patent/HUP0101614A3/hu not_active Application Discontinuation
- 1999-02-23 PT PT99906341T patent/PT1056850E/pt unknown
- 1999-02-23 JP JP2000532517A patent/JP2002504328A/ja active Pending
-
2000
- 2000-08-22 NO NO20004195A patent/NO328139B1/no not_active IP Right Cessation
-
2003
- 2003-07-11 US US10/618,570 patent/US7208291B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987005026A1 (en) * | 1986-02-24 | 1987-08-27 | The Trustees Of Columbia University In The City Of | Dna encoding streptavidin, streptavidin produced therefrom, fused polypeptides which include amino acid sequences present in streptavidin and uses thereof |
WO1997019957A1 (en) * | 1995-11-30 | 1997-06-05 | New York University | High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein |
Non-Patent Citations (1)
Title |
---|
FASEB J., vol.9(6), pp.A1395, 1995.4.24. * |
Also Published As
Publication number | Publication date |
---|---|
ATE274058T1 (de) | 2004-09-15 |
WO1999042577A3 (en) | 1999-10-21 |
HUP0101614A2 (hu) | 2001-09-28 |
AU750444B2 (en) | 2002-07-18 |
AU2631299A (en) | 1999-09-06 |
WO1999042577A2 (en) | 1999-08-26 |
JP2002504328A (ja) | 2002-02-12 |
ES2226340T3 (es) | 2005-03-16 |
CA2319039A1 (en) | 1999-08-26 |
NO20004195L (no) | 2000-08-22 |
US20040185059A1 (en) | 2004-09-23 |
CN1195852C (zh) | 2005-04-06 |
PT1056850E (pt) | 2004-12-31 |
DK1056850T3 (da) | 2004-11-29 |
EP1056850A2 (en) | 2000-12-06 |
NO328139B1 (no) | 2009-12-14 |
PL343079A1 (en) | 2001-07-30 |
DE69919515D1 (de) | 2004-09-23 |
KR20010085196A (ko) | 2001-09-07 |
CN1291230A (zh) | 2001-04-11 |
US7208291B2 (en) | 2007-04-24 |
HUP0101614A3 (en) | 2006-04-28 |
EP1056850B1 (en) | 2004-08-18 |
PL195990B1 (pl) | 2007-11-30 |
NO20004195D0 (no) | 2000-08-22 |
DE69919515T2 (de) | 2005-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100373813B1 (ko) | 이관능성단백질,그의제조및용도 | |
US7638281B2 (en) | Polypeptide, cDNA encoding the same and use of them | |
US7423139B2 (en) | High level expression of recombinant human erythropoietin having a modified 5′-UTR | |
US20200246420A1 (en) | pHLIP® peptide-mediated epitope tethering at cell surfaces | |
JP6574175B2 (ja) | 細胞透過性ペプチド、及びそれを含むコンジュゲート | |
KR100629185B1 (ko) | 인간 리조포스파티드산 수용체 물질 및 그 용도 | |
KR100722578B1 (ko) | 비오틴-결합 수용체 분자 | |
US5925548A (en) | Modified receptors that continuously signal | |
US20090011984A1 (en) | Biotin-binding receptor molecules | |
WO2002070552A2 (de) | POLYPEPTIDE EINES HDM2-PROTEIN SPEZIFISCHEN MURINEN Α/β T-ZELL REZEPTORS, DIESE KODIERENDE NUKLEINSÜREN UND DEREN VERWENDUNG | |
US8101736B2 (en) | Polynucleotides and polypeptide of human KV1.3, compositions comprising same and methods of using same | |
JP2002504328A5 (ko) | ||
MXPA00007931A (en) | Biotin-binding receptor molecules | |
JP2003526323A (ja) | Kdel受容体インヒビター | |
CA2410525A1 (en) | Fas ligand-fused proteins | |
EP0473080A2 (en) | Chondromodulin-I protein | |
ES2264564T3 (es) | Factor de crecimiento htter36. | |
TW200902545A (en) | Compositions and methods of using CRMP-1 and its fragments for treating cancer | |
AU773085B2 (en) | Transfer compounds, the production and the use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
LAPS | Lapse due to unpaid annual fee |